nach oben

Erschienen in:

31.01.2023 | Original articles

Analysis of risk factors for systemic inflammatory response syndrome in patients after transcatheter aortic valve replacement

verfasst von: Jifang Cheng, Mingqi Dong, Chunjie Wen, Bin Yu, Jiaqi Fan

Erschienen in: Herz | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Our aim was to determine the risk factors of postoperative systemic inflammatory response syndrome (SIRS) in patients with transcatheter aortic valve replacement (TAVR), identify those with a high risk of SIRS, and help reduce SIRS occurrence.

Methods

A retrospective cohort study was conducted to collect the clinical data of patients who underwent TAVR from January 2014 to December 2019 at a tertiary hospital in Zhejiang Province. The study included 156 men and 94 women. Patients were divided into SIRS and non-SIRS groups. The pre-, intra-, and postoperative indices of the two groups were recorded. The data of the two groups were compared, and univariate analysis was performed. All statistically significant factors were assessed using binary logistic regression analysis to clarify the risk factors of SIRS after TAVR.

Results

Overall, 30 patients developed SIRS after TAVR, with an incidence rate of 12%, an odds ratio (OR) of 0.571, and a 95% confidence interval (CI) of 0.469–0.694 (p = 0.000). There was a significant correlation between SIRS and glucose (OR: 0.823, 95% CI: 0.678–1.000, p = 0.049), albumin (OR: 0.938, 95% CI: 0.881–0.998, p = 0.044), brain natriuretic peptide (OR: 1.000, 95% CI: 1.000–1.000, p = 0.010), sex (OR: 0.412, 95% CI: 0.190–0.892, p = 0.025), and history of hypertension (OR: 0.375, 95% CI: 0.169–0.819, p = 0.014). Multivariate regression analysis demonstrated that age (OR: 1.190, 95%CI: 1.073–1.319, p = 0.001) and body mass index (BMI; OR: 0.559, 95% CI: 0.447–0.698, p = 0.000) were independent risk factors for postoperative SIRS in patients with TAVR.

Conclusion

The incidence of SIRS after TAVR was 12%. There was a significant correlation between SIRS and albumin, glucose, and hypertension. The independent risk factors for SIRS after TAVR were age and BMI.

Kanwar A, Thaden JJ, Nkomo VT (2018) Management of patients with aortic valve stenosis. Mayo Clin Proc 93(4):488–508. https://doi.org/10.1016/j.mayocp.2018.01.020CrossRefPubMed

Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366(18):1686–1695. https://doi.org/10.1056/NEJMoa1200384CrossRefPubMed

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R et al (2021) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention 60(4):727–800. https://doi.org/10.4244/eij-e-21-00009CrossRef

Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, Pilgrim T, Petrinic T, Nikolakopoulou A, Salanti G et al (2019) Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 40(38):3143–3153. https://doi.org/10.1093/eurheartj/ehz275CrossRefPubMed

Otto CM (2019) Informed shared decisions for patients with aortic stenosis. N Engl J Med 380(18):1769–1770. https://doi.org/10.1056/NEJMe1903316CrossRefPubMed

Gorla R, Erbel R, Eagle KA, Bossone E (2018) Systemic inflammatory response syndromes in the era of interventional cardiology. Vasc Pharmacol 107:53–66. https://doi.org/10.1016/j.vph.2018.04.003CrossRef

Schwietz T, Behjati S, Gafoor S, Seeger F, Doss M, Sievert H, Zeiher AM, Fichtlscherer S, Lehmann R (2015) Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves. EuroIntervention 10(12):1468–1473. https://doi.org/10.4244/eijy14m06_05CrossRefPubMed

Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A, Vatterott AM, Lawler C, Damiano RJ, Moon MR et al (2015) Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement. Heart 101(7):537–545. https://doi.org/10.1136/heartjnl-2014-307057CrossRefPubMed

Rettig TC, Rigter S, Nijenhuis VJ, van Kuijk JP, ten Berg JM, Heijmen RH, van de Garde EM, Noordzij PG (2015) The systemic inflammatory response syndrome predicts short-term outcome after transapical transcatheter aortic valve implantation. J Cardiothorac Vasc Anesth 29(2):283–287. https://doi.org/10.1053/j.jvca.2014.10.005CrossRefPubMed

10.

Tirado-Conte G, Freitas-Ferraz AB, Nombela-Franco L, Jimenez-Quevedo P, Biagioni C, Cuadrado A, Nuñez-Gil I, Salinas P, Gonzalo N, Ferrera C et al (2016) Incidence, causes, and impact of in-hospital infections after transcatheter aortic valve implantation. Am J Cardiol 118(3):403–409. https://doi.org/10.1016/j.amjcard.2016.05.012CrossRefPubMed

11.

Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag G, Borst HG (1996) Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61(6):1714–1720. https://doi.org/10.1016/0003-4975(96)00055-0CrossRefPubMed

12.

Jansen F, Rohwer K, Vasa-Nicotera M, Mellert F, Grube E, Nickenig G, Werner N, Sinning JM (2016) CD-144 positive endothelial microparticles are increased in patients with systemic inflammatory response syndrome after TAVI. Int J Cardiol 204:172–174. https://doi.org/10.1016/j.ijcard.2015.11.179CrossRefPubMed

13.

Erdoes G, Lippuner C, Kocsis I, Schiff M, Stucki M, Carrel T, Windecker S, Eberle B, Stueber F, Book M (2015) Technical approach determines inflammatory response after surgical and transcatheter aortic valve replacement. PLoS ONE 10(11):e143089. https://doi.org/10.1371/journal.pone.0143089CrossRefPubMedPubMedCentral

14.

Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, Müller C, Vasa-Nicotera M, Grube E, Nickenig G et al (2012) Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 33(12):1459–1468. https://doi.org/10.1093/eurheartj/ehs002CrossRefPubMed

15.

Rettig TCD, Nijenhuis VJ, Meek B, Rigter S, Ten Berg JM, Vlaminckx B, van Klei WA, van de Garde EMW, Peelen LM, Noordzij PG (2018) Systemic inflammation after transcatheter aortic valve implantation: a prospective exploratory study. J Cardiothorac Vasc Anesth 32(4):e77–e82. https://doi.org/10.1053/j.jvca.2017.12.051CrossRefPubMed

16.

Xiang J, He L, Li D, Peng T, Wei S (2021) Analysis of risk factors for systemic inflammatory response syndrome after thoracic aortic repair. J Clin Cardiol 37(05):468–472

17.

Witberg G, Kornowski R, Vaknin-Assa H, Codner P, Bental T, Yahav D, Goldberg E, Perl L, Schwartzenberg S, Sagie A et al (2021) Temporary trends in fever following transcatheter aortic valve implantation. Cardiology 146(3):359–367. https://doi.org/10.1159/000511621CrossRefPubMed

18.

Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM (2019) Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE 14(1):e201196. https://doi.org/10.1371/journal.pone.0201196CrossRefPubMedPubMedCentral

19.

Cheng J, Wen C, Jiang S, Zhu X, Zhang L, Chen S, Liu X, He W, Kong M, Fan J (2021) Study on risk factors of systemic inflammatory response syndrome after transcatheter aortic valve replacement. Chin J Emerg Med 30(12):1506–1509

20.

Gardner ID (1980) The effect of aging on susceptibility to infection. Rev Infect Dis 2(5):801–810. https://doi.org/10.1093/clinids/2.5.801CrossRefPubMed

21.

Yuan Y, Huang T, Wang G (2012) Relationship between pulmonary infection and metabolic syndrome after cardiac valve replacement in women. Chin J Nosocomiol 22(12):2545–2546

Titel: Analysis of risk factors for systemic inflammatory response syndrome in patients after transcatheter aortic valve replacement
verfasst von: Jifang Cheng
Mingqi Dong
Chunjie Wen
Bin Yu
Jiaqi Fan
Publikationsdatum: 31.01.2023
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 5/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-023-05163-9

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Analysis of risk factors for systemic inflammatory response syndrome in patients after transcatheter aortic valve replacement

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Koronare CT-Angiographie und koronare Atherosklerose

Bildgebende Diagnostik der kardialen Sarkoidose

Atrial fibrillation increases the risk of new-onset myocardial infarction amongst working-age population: a propensity-matched study

Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2+/- atrial cardiomyocytes

Computed tomography to guide transcatheter aortic valve implantation

Echokardiographie mit hohen Bildraten in der klinischen Praxis

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie